Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1668-1675
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1668
Primary pancreatic peripheral T-cell lymphoma: A case report
Yan-Liang Bai, Li-Jie Wang, Hui Luo, Ya-Bin Cui, Jin-Hui Xu, Hui-Jie Nan, Pei-Yao Yang, Jun-Wei Niu, Ming-Yue Shi
Yan-Liang Bai, Jin-Hui Xu, Hui-Jie Nan, Pei-Yao Yang, Jun-Wei Niu, Ming-Yue Shi, Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China
Li-Jie Wang, Ya-Bin Cui, Department of Hematology, Henan University People's Hospital and Henan Provincial People's Hospital, Zhengzhou 450003, Henan Province, China
Hui Luo, Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China
Co-first authors: Yan-Liang Bai and Li-Jie Wang.
Author contributions: Bai YL and Wang LJ contributed equally to this work. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Supported by National Natural Science Foundation of China, No. 81971508; and The Health Bureau of Henan Province, P.R. China, No. LHGJ20190579.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Yue Shi, Doctor, DPhil, MD, Staff Physician, Department of Hematology, Zhengzhou University People's Hospital and Henan Provincial People's Hospital, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. shimingyue16@gmail.com
Received: December 30, 2023
Peer-review started: December 30, 2023
First decision: January 13, 2024
Revised: January 25, 2024
Accepted: February 29, 2024
Article in press: February 29, 2024
Published online: April 15, 2024
Processing time: 102 Days and 7.4 Hours
Abstract
BACKGROUND

Primary pancreatic lymphoma (PPL) is an exceedingly rare tumor with limited mention in scientific literature. The clinical manifestations of PPL are often nonspecific, making it challenging to distinguish this disease from other pancreatic-related diseases. Chemotherapy remains the primary treatment for these individuals.

CASE SUMMARY

In this case study, we present the clinical details of a 62-year-old woman who initially presented with vomiting, abdominal pain, and dorsal pain. On further evaluation through positron emission tomography-computed tomography, the patient was considered to have a pancreatic head mass. However, subsequent endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) revealed that the patient had pancreatic peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). There was a substantial decrease in the size of the pancreatic mass after the patient underwent a cycle of chemotherapy comprised of brentuximab vedotin, gemcitabine, and oxaliplatin (brentuximab vedotin and Gemox). The patient had significant improvement in radiological findings at the end of the first cycle.

CONCLUSION

Primary pancreatic PTCL-NOS is a malignant and heterogeneous lymphoma, in which the clinical manifestations are often nonspecific. It is difficult to diagnose, and the prognosis is poor. Imaging can only be used for auxiliary diagnosis of other diseases. With the help of immunostaining, EUS-FNA could be used to aid in the diagnosis of PPL. After a clear diagnosis, chemotherapy is still the first-line treatment for such patients, and surgical resection is not recommended. A large number of recent studies have shown that the CD30 antibody drug has potential as a therapy for several types of lymphoma. However, identifying new CD30-targeted therapies for different types of lymphoma is urgently needed. In the future, further research on antitumor therapy should be carried out to improve the survival prognosis of such patients.

Keywords: Pancreatic cancer; Lymphoma; Chemotherapy; Primary pancreatic lymphoma; Case report

Core Tip: Primary pancreatic lymphoma is an extremely uncommon tumor with nonspecific clinical symptoms, making it challenging to distinguish this disease from other pancreatic-related diseases. In this case, we present the clinical details of a 62 woman who initially presented with vomiting, abdominal pain, and dorsal discomfort. Endoscopic ultrasonography-guided fine needle aspiration revealed the diagnosis of pancreatic peripheral T-cell lymphoma, not otherwise specified. There was a substantial decrease in the size of the pancreatic mass after the patient underwent a cycle of chemotherapy comprised of brentuximab vedotin, gemcitabine, and oxaliplatin. We have further summarized these illnesses to clarify their etiology.